Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic Licenses TB Technology from Qiagen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mayo Clinic today announced it has licensed patent rights from Qiagen that will allow Mayo Medical Laboratories to offer a test for M. tuberculosis complex speciation.

Financial and other terms of the deal were not disclosed.

In an e-mail, Nancy Wengenack, associate professor of Laboratory Medicine and Pathology at the Mayo Medical School College of Medicine, said that the new test will be PCR-based and use fluorescence resonance energy transfer hybridization probes for detection.

In a statement, Mayo said that the Qiagen-based test will expand its current offering of tuberculosis testing, which includes M. tuberculosis complex culture, molecular identification, and drug susceptibility testing.

Mayo also offers PCR-based testing for M. tuberculosis complex directly from specimens and molecular detection of drug-resistance markers for the drugs isoniazid and pyrazinamide.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.